1. Home
  2. NOAH vs ALT Comparison

NOAH vs ALT Comparison

Compare NOAH & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NOAH

Noah Holdings Limited

N/A

Current Price

$7.58

Market Cap

653.4M

Sector

Finance

ML Signal

N/A

Logo Altimmune Inc.

ALT

Altimmune Inc.

N/A

Current Price

$2.62

Market Cap

573.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NOAH
ALT
Founded
2005
1997
Country
Singapore
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
653.4M
573.8M
IPO Year
2010
2005

Fundamental Metrics

Financial Performance
Metric
NOAH
ALT
Price
$7.58
$2.62
Analyst Decision
Buy
Strong Buy
Analyst Count
4
10
Target Price
$10.62
★ $17.11
AVG Volume (30 Days)
90.5K
★ 3.1M
Earning Date
11-24-2026
11-05-2026
Dividend Yield
★ 9.11%
N/A
EPS Growth
N/A
★ 25.37
EPS
★ N/A
N/A
Revenue
N/A
★ $41,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$13.29
★ N/A
Revenue Growth
N/A
★ 105.00
52 Week Low
$7.60
$2.55
52 Week High
$12.45
$6.44

Technical Indicators

Market Signals
Indicator
NOAH
ALT
Relative Strength Index (RSI) 29.08 27.07
Support Level N/A $2.57
Resistance Level $8.17 $3.35
Average True Range (ATR) 0.17 0.12
MACD -0.01 -0.05
Stochastic Oscillator 3.65 6.29

Price Performance

Historical Comparison
NOAH
ALT

About NOAH Noah Holdings Limited

Noah Holdings Ltd is a wealth management service provider offering comprehensive advisory services on investment and asset allocation, mainly for Mandarin-speaking high-net-worth (HNW) investors. The company's operating segments are Domestic public securities, Domestic asset management, Domestic insurance, Overseas wealth management, Overseas asset management, Overseas insurance and comprehensive services, and Headquarters. Maximum revenue is generated from its Domestic asset management business, which manages private equity funds, real estate equity funds, and private secondary products. The domestic asset management operations focus on managing primary market exits and cross-border ETF products in the secondary market. Geographically, it derives maximum revenue from Mainland China.

About ALT Altimmune Inc.

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: